RxDoctor Payments DataLook up a doctor →

Max Mercado, MD

Internal Medicine · Philadelphia, PANPI 1336151182

Payments from drug & device makers

$564,889in general payments, 2019–2025

Across 1,617 payments — averaging $349.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$239K
  • Modernatx, Inc.$71K
  • Novartis$68K
  • AstraZeneca$68K
  • Currax Pharmaceuticals LLC$64K
  • AbbVie$22K
  • plus $34K from 54 others

What the payments were for

  • Consulting fees$5,41010%
  • Speaking & faculty fees$16,96433%
  • Travel & lodging$5,11210%
  • Food & beverage$24,38947%
  • Education$960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.35$238,894
Modernatx, Inc.30$70,950
Novartis40$67,950
AstraZeneca110$67,910
Currax Pharmaceuticals LLC24$63,674
AbbVie(2 entities)221$21,518
Exact Sciences13$10,886
Novo Nordisk158$3,738
Alnylam Pharmaceuticals Inc.4$2,416
Lilly USA, LLC107$1,784
GSK114$1,706
Biohaven Pharmaceuticals, Inc.9$1,341
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC108$1,156
Amgen79$1,150
Pfizer64$871
Boehringer Ingelheim42$773
Johnson & Johnson(2 entities)31$614
Sanofi-aventis U.S. LLC31$574
Merck33$549
Bayer25$421
Esperion Therapeutics, Inc.13$386
Abbott18$380
Corcept Therapeutics27$345
Astellas Pharma US Inc14$282
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)13$271
Alfasigma USA, Inc.4$246
Teva Pharmaceuticals USA, Inc.15$226
Radius Health, Inc.12$219
Arbor Pharmaceuticals, Inc.13$219
Kowa Pharmaceuticals America, Inc.22$214
OPKO Pharmaceuticals, LLC18$201
Otsuka America Pharmaceutical, Inc.12$201
Intra-sana Laboratories15$199
Lundbeck LLC10$196
Daiichi Sankyo Inc.5$191
E.r. Squibb & Sons, L.L.C.14$188
Amarin Pharma, Inc.9$177
Takeda Pharmaceuticals U.S.A., Inc.12$158
Ironwood Pharmaceuticals, Inc8$119
Biohaven Pharmaceutical Holding Company Ltd.6$118
Medtronic5$108
Shield Therapeutics Inc1$89
Idorsia Pharmaceuticals US Inc5$87
Xeris Pharmaceuticals, Inc.4$76
Inspire Medical Systems, Inc.4$75
Sumitomo Pharma America, Inc.3$68
Supernus Pharmaceuticals, Inc.4$67
Nestle Healthcare Nutrition Inc.4$66
Axsome Therapeutics, Inc.3$62
Scilex Pharmaceuticals Inc.3$53
BD2$51
Eisai Inc.3$50
Ultragenyx Pharmaceutical Inc.2$45
Philips North America LLC3$41
Mylan Specialty L.p.2$37
Biogen2$36
Althera Pharmaceuticals LLC3$35
Almatica Pharma LLC2$33
Aimmune Therapeutics, Inc.2$32
Sunovion Pharmaceuticals Inc.2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$564,889 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$61,381
Medicare patients
83
Services billed
1,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide538$546,068
EliquisApixaban313$310,881
MounjaroTirzepatide191$214,584
TrulicityDulaglutide203$212,384
LinzessLinaclotide261$165,195
FarxigaDapagliflozin Propanediol181$145,615
RybelsusSemaglutide111$143,472
JardianceEmpagliflozin167$132,508
Trelegy ElliptaFluticasone/Umeclidin/Vilanter202$128,439
Xigduo XrDapaglifloz Propaned/Metformin179$127,514
Tresiba Flextouch U-200Insulin Degludec149$104,797
VraylarCariprazine Hcl65$87,074
EntrestoSacubitril/Valsartan92$86,816
JanuviaSitagliptin Phosphate124$86,145
XareltoRivaroxaban64$73,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$3,738$740,762695 claims
Lilly USA, LLCMounjaro, Trulicity$1,784$426,968394 claims
PfizerEliquis$871$310,881313 claims
AbbVieLinzess, Vraylar, Qulipta, Namzaric$21,518$286,181359 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Synjardy Xr$773$227,496294 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,706$195,274364 claims
AstraZenecaFarxiga$67,910$145,615181 claims
MerckJanuvia, Janumet Xr$549$124,832180 claims
NovartisEntresto$67,950$86,81692 claims
Johnson & JohnsonXarelto$614$73,61764 claims
Arbor Pharmaceuticals, Inc.Edarbi$219$54,717125 claims
AmgenProlia$1,150$45,78629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →